Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense
F G Hayden, R Fritz, M C Lobo, W Alvord, W Strober, S E Straus, F G Hayden, R Fritz, M C Lobo, W Alvord, W Strober, S E Straus
Abstract
To further understand the role of cytokine responses in symptom formation and host defenses in influenza infection, we determined the levels of IL-1beta, IL-2, IL-6, IL-8, IFN-alpha, TGF-beta, and TNF-alpha in nasal lavage fluid, plasma, and serum obtained serially from 19 volunteers experimentally infected with influenza A/Texas/36/91 (H1N1) and correlated these levels with various measures of infection and illness severity. We found that IL-6 and IFN-alpha levels in nasal lavage fluids peaked early (day 2) and correlated directly with viral titers, temperature, mucus production, and symptom scores. IL-6 elevations were also found in the circulation at this time point. In contrast, TNF-alpha responses peaked later (day 3 in plasma, day 4 in nasal fluids), when viral shedding and symptoms were subsiding. Similarly, IL-8 peaked late in the illness course (days 4-6) and correlated only with lower respiratory symptoms, which also occurred late. None of IL-1beta, IL-2, or TGF-beta levels increased significantly. These data implicate IL-6 and IFN-alpha as key factors both in symptom formation and host defense in influenza.
References
- J Infect Dis. 1982 Jun;145(6):837-41
- J Clin Invest. 1996 Jan 15;97(2):421-30
- Annu Rev Immunol. 1990;8:253-78
- Cell Immunol. 1990 Aug;129(1):104-11
- J Immunol. 1991 Nov 15;147(10):3507-13
- Lab Anim Sci. 1992 Jun;42(3):222-32
- J Immunol. 1992 Aug 1;149(3):932-9
- FEBS Lett. 1992 Sep 14;309(3):327-9
- J Clin Oncol. 1993 Mar;11(3):499-506
- J Allergy Clin Immunol. 1993 Sep;92(3):457-65
- Reg Immunol. 1993 May-Aug;5(3-4):142-50
- Immunobiology. 1993 Nov;189(3-4):340-55
- Am J Physiol. 1995 Jan;268(1 Pt 2):R78-84
- J Infect Dis. 1995 Mar;171(3):584-92
- J Immunol. 1996 Feb 1;156(3):1138-42
- Microb Pathog. 1995 Sep;19(3):175-83
- Res Virol. 1996 Mar-Jun;147(2-3):123-30
- J Allergy Clin Immunol. 1996 Dec;98(6 Pt 1):1080-7
- N Engl J Med. 1997 Jan 30;336(5):347-56
- Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):634-9
- J Exp Med. 1997 Feb 3;185(3):461-9
- J Exp Med. 1997 Apr 7;185(7):1185-92
- J Gen Virol. 1990 Feb;71 ( Pt 2):477-9
Source: PubMed